Published: 18 February 2021
Author(s): Irene Marzona, Marco Proietti, Pierluca Colacioppo, Andreana Foresta, Marta Baviera
Issue: June 2021
Section: Letter to the editor

Non-vitamin K antagonist oral anticoagulants (NOACs) were marketed in 2011 as alternatives to Vitamin K Antagonists (VKA) for treatment of thromboembolic risk in atrial fibrillation (AF) patients. Pivotal studies demonstrated the non-inferior effectiveness and the superior safety of NOACs compared to VKAs. International guidelines currently recommend NOACs over VKAs for thromboprophylaxis of AF [1], leading to a progressive uptake of NOACs [2]. One of the crucial aspect in the management of NOACs, is the appropriate choice of the drug dose [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.